Cost-effectiveness analysis of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy for advanced HER2-negative gastric or gastro-esophageal junction cancer.

ABSTRACT:

Background

Ramucirumab in combination with paclitaxel has demonstrated substantial antitumor activity in the treatment of advanced human epidermal growth factor receptor-2 (HER2)-negative gastric cancer (GC) or gastro-esophageal junction cancer (GEJC). However, the cost-effectiveness of this regimen in this patient population remains uncertain, particularly within the Chinese healthcare context.

Objective

This study aimed to assess the cost-effectiveness of ramucirumab plus paclitaxel as a switch maintenance regimen compared to continuing first-line chemotherapy for patients with advanced HER2-negative GC or GEJC, from the perspective of the Chinese healthcare system.

Design

A health economic evaluation was conducted to compare two treatment strategies.

Methods

SUBMITTER: Lang Y 

PROVIDER: S-EPMC12441278 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature